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Abstract
Background: p16INK4a (p16) is a well-recognized surrogate molecular marker for human papilloma virus (HPV) related squamous dysplasia. Our hypothesis is that the invasive interventions and
related morbidities could be avoided by objective stratification of positive cytologic interpretations
by p16 immunostaining of cell block sections of cytology specimens. Materials and Methods:
Nuclear immunoreactivity for p16 was evaluated in cell block sections in 133 adequate cases [20
negative for intraepithelial lesion or malignancy, 28 high-grade squamous intraepithelial lesion
(HSIL), 50 low-grade squamous intraepithelial lesion (LSIL), 21 atypical squamous cells, cannot
exclude HSIL (ASC-H), and 14 atypical squamous cells of undetermined significance (ASCUS)]
and analyzed with cervical biopsy results. Results: (a) HSIL cytology (28): 21 (75%) were p16
positive (11 biopsies available — 92% were positive for cervical intraepithelial neoplasia (CIN) 1
and above) and 7 (25%) were p16 negative (3 biopsies available — all showed only HPV with small
atypical parakeratotic cells). (b) LSIL cytology (50): 13 (26%) cases were p16 positive (12 biopsies
available — all were CIN1 or above) and 37 (74%) were p16 negative (12 biopsies available — all
negative for dysplasia. However, 9 (75%) of these biopsies showed HPV). (c) ASC-H cytology (21):
14 (67%) were p16 positive (6 biopsies available — 5 showed CIN 3/Carcinoma in situ/Ca and 1
showed CIN 1 with possibility of under-sampling. Cytomorphologic re-review favored HSIL) and
7 (33%) were p16 negative (5 biopsies available — 3 negative for dysplasia. Remaining 2 cases — 1
positive for CIN 3 and 1 showed CIN 1 with scant ASC-H cells on cytomorphologic re-review
with possibility under-sampling in cytology specimen). (d) ASCUS cytology (14): All (100%) were
p16 negative on cell block sections of cervical cytology specimen. HPV testing performed in last 6
months in 7 cases was positive in 3 (43%) cases. Conclusion: p16 immunostaining on cell block
sections of cervical cytology specimens showed distinct correlation patterns with biopsy results.
Reflex p16 immunostaining of cell blocks based on the algorithmic approach to be evaluated by a
multiinstitutional comprehensive prospective study is proposed.
Key words: Cervical cancer, cervical cytology, immunohistochemistry, p16, Pap test, reflex testing,
screening, squamous intraepithelial neoplasia
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INTRODUCTION
Globally, after breast cancer, carcinoma of cervix is the
second most frequent cancer in women.[1] Detection of
cervical premalignant lesions is a crucial component to
reduce the associated morbidity and mortality. Over the
years, cervical cytology (Pap test) has proven to be a very
effective screening tool to achieve this goal, reducing
the incidence from 14.8 per 100,000 in 1975 to 6.5 per
100,000 in 2006 in the United States[2] and trends show
a significant fall in incidence of 3.5% every year for the
last ten years, until 2006.[3] However, it is desirable to
increase the specificity of this screening test. Any management algorithm that results in fewer false positives
would be beneficial in preventing the complications of
over-treatment.[4]
p16INK4a (p16), as a surrogate molecular marker of Human
Papilloma Virus (HPV) related squamous dysplasia, has been
relatively well established in cervical biopsy specimens[5–8]
with excellent inter- and intraobserver reproducibility.[7]
Its application to cervical cytology specimens has also
been evaluated. However, the main challenge in our experience in applying p16 to cytology preparations is the
inherent difficulty in interpretation of diagnostic nuclear
immunoreactivity for p16 in whole cells with nucleus
enveloped by surrounding cytoplasm due to the obscuring
cytoplasmic immunoreactivity. As a result, reproducible
and objective interpretation of p16 immunoreactivity in
cytologic preparations especially with relatively few diagnostic intact cells is inherently suboptimal.[9,10] Performing immunohistochemistry (IHC) on cell block sections
of cytologic specimens could circumvent this limitation.
However, preparation of cell blocks from liquid-based cytology (LBC) specimens with singly scattered cells may not
produce cell block sections with reproducible cellularity.[11]
We applied a protocol specially standardized to produce
cell blocks from cytology specimens with single scattered
cells such as in LBC specimens.[11] This protocol included
a centrifugation step to align the dispersed solitary and
small groups of cells in LBC specimens along the flat cutting surface of the cell block. A visible dark colored marker
was included to monitor the depth of section cutting. By
utilizing this protocol, the cell block sections showed a
reproducible adequate cellularity. In this study, we evaluated application of p16 immunoreactivity in cell block
sections prepared by this method from the residual SurePath™ specimen (TriPath Imaging, Burlington, NC) (SP).
Our hypothesis is that ancillary reflex application of p16
immunostaining on cell block sections of cytology specimens
could subcategorize atypical squamous cells of undetermined
significance (ASCUS) and low-grade squamous intraepithelial lesion (LSIL) into cases with and without dysplasia.
Similarly, atypical squamous cells, cannot exclude HSIL
(ASC-H) and high-grade squamous intraepithelial lesion
2
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(HSIL) could be confirmed for dysplasia with increased
objectivity. This approach would avoid invasive interventions and prevent potentially increased morbidities by
utilizing objective options at the minimally invasive cervical cytology stage. Developing and adopting appropriate
algorithms based on results of larger, comprehensive,
multiinstitutional trial with reflex testing (p16 and other
markers such as HPV L1 capsid protein[12] and Ki67)[13] on
specially prepared cell blocks of cervical cytology specimens may be indicated.

MATERIALS AND METHODS
In this study, performed after approval from institutional
review board (IRB), cell blocks were made from LBC
specimens obtained from patients ranging 18 to 70 years
of age. Out of approximately 120,000 gynecologic cytology specimens examined over a 2-year period, residual
LBC specimens with positive cytopathologic interpretations (ASCUS and above) were available in 114 cases (in
addition to 20 negative cases) for cell block preparation.
The limiting factors controlling this final number included: (a)
adequate cellularity of LBC, (b) availability of residual
LBC specimen subject to reflex testing such as HPV test,
(c) unavoidable logistic complexities related to selection of specimen for the study including multiplicity of
cytopathologists–cytotechnologists involved with initial
cytopathologic evaluation, (d) selection of representative
numbers in each category of positive squamous lesions,
and (e) practical limitations related to procurement of the
residual specimen prior to its final disposal. These factors
could not be controlled reproducibly to achieve inclusion
of all cases based on limitations related to expedited IRB
in smaller studies such as the present study.
Twenty cell blocks were prepared from cases with negative
results and showing an uneventful follow-up pattern based
on consecutive negative cervical cytologies and/or biopsies for one year. A total of 114 cell blocks were prepared
from specimens with positive cytopathologic interpretations
for squamous epithelial lesions (ASCUS and above). We
used a standardized protocol for cell block preparation of
specimens with singly scattered individual cells or small
groups of cells using HistoGel™.[11] The protocol achieves
alignment and concentration of the cells in the sample
along the cutting surface of the cell block. It also includes
AV-marker which serves to visualize the level at which the
cells are concentrated. It allows selection of the sections
from the plane of the cell block with the highest concentration of cells by the technologist during section cutting.
For actual methodology, please refer to recently published
video article which describes the technical details and is
available as free publication in open access.[11]
Three unstained, serial, cell block sections (one
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for hematoxylin and eosin (H & E) staining, one for
p16 immunostaining, and one spare for elective
immunostaining) were cut from each cell block. H &
E stained sections were evaluated morphologically for
cellularity. Cell blocks with sections showing more than
100 cells (either singly scattered or in cohesive groups) or
showing any number of epithelial cells with morphological atypia were considered adequate. One (out of total
134) cell block was relatively hypocellular without morphological atypia and was not included in the study. The
cytopathologic interpretations of 133 cases evaluated by
p16 immunostaining of cell block sections included 20
negative for intraepithelial lesion or malignancy (NILM),
28 HSIL, 50 LSIL, 21 ASC-H, and 14 ASCUS [Figure 1].
One section from each of finally selected 133 cell blocks
was immunostained for p16 [Table 1] with appropriate
positive and negative controls for each batch.

The p16 immunoreactivity patterns included: (a) none,
(b) cytoplasmic alone, (c) nuclear alone, and (d) nuclear
with cytoplasmic. Only nuclear and nuclear with cytoplasmic
immunostaining were considered positive. None or only cytoplasmic immunostaining was considered negative.[10,14-16]
Cell block sections prepared from 20 cases with negative
cytologic interpretation showed lack of nuclear (with
or without cytoplasmic) immunoreactivity for p16 in
squamous cells. Based on the previous study[14] and many
published studies,[9,17-19] the p16 antibody clone used in
this study (E6H4) showed excellent results.
The follow-up cervical biopsy results were available in 49
cases (15 out of 28 HSIL, 10 out of 21 ASC-H, and 24 out
of 50 LSIL). Biopsy results were not available/performed in
all 14 cases with ASCUS. The cervical biopsy was considered

Out of 120000 SurePathTM (LBC) samples
Over 2 year period
We could get residual LBC in 134 cases
for cell block preparaon from adequately cellular residual LBC specimens.
3 slides with consecuve serial cell block secons were cut.
One secon was stained with H & E stain, and
One adjacent level serial secon was used for p16 immunostaining.
Remaining slide with addional serial secon of cell block was stored for elecve immunohistochemistry.
133 cases showed adequate cellularity in H&E stained cell block secons.
(at least 100 cells in each secon or abnormal cells corresponding with cytopathologic features seen in cytology prep)
1 case had inadequate cellularity due to technical limitaon.
Out of 133 cases with adequately cellular cell blocks,
20 were interpreted cytologically as NILM (with negave cytology or biopsy in immediate past 12 months).
113 cases with adequate cellularity and with posive cytopathologic interpretaon (ASCUS & above)
(28 HSIL, 50 LSIL,21 ASC-H, 14 ASCUS)
Availability and quality of cell block preparaons was dependent on a) adequate cellularity of LBC,
b) availability of residual LBC specimen subject to reflex testing such as HPV test,
c) unavoidable logisc complexies related to selecon of specimen for the study including mulplicity of
cytoptahologists-cytotechnologists involved with inial cytopathologic evaluaon, and
d) selecon of representave numbers in each category of posive squamous lesions.
133 cell blocks- secons- evaluated by p16 immunostaining

Interpret

Figure 1: Selection and evaluation of 20 negative and 113 abnormal cases included in the study.

Table 1: Immunostaining of cell block sections with p16
Clone

Source

Dilution

Duration

Pretreatment

E6H4

mtm laboratories AG

Proprietary
(pre-diluted)

30 min

Heat-induced epitope retrieval (35 min at 99°C, followed
by 20 min cool off at room temperature) in citrate buffer,
pH 6.0
3
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positive if it was reported as CIN1 or greater (confirmed
with p16 IHC of biopsy sections in equivocal cases). Negative for dysplasia with or without HPV cytopathic effects were
included for this study in the negative category.
The specimens were available for cell block preparation
in 134 cases, because HPV DNA testing (HPVT) was not
requested on the residual cervical cytology specimen. In
cases with ASCUS interpretations, results of HPVT performed in last 6 months could be obtained in seven cases.

RESULTS
Correlation of p16 immunostaining on cell block sections
of LBC specimens with biopsy results is shown in Table
2. The morphology of p16 immunostained cells in cell
block sections in various groups is illustrated in Figures
2–4. Trouble shooting of false-positive and false-negative
cases predominantly revealed sampling and biopsy interpretation issues. Cytoplasmic immunoreactivity alone was
observed in scant cells in two cases.

I. Twenty-eight cases with HSIL cytology

a.		 Twenty-one (75%) cases showed positive results with
p16. Out of these, 12 had follow-up biopsies. Eleven (92%) biopsies were positive. The 75% (9/12)
of these cases showed CIN 2–3 or invasive carcinoma (Ca), 2 showed CIN 1, and one was negative
for dysplasia. Further analysis of three cases with
CIN1 or lower lesions suggested potential undersampling in biopsy based on cyto–histo findings
(with unequivocal cytomorphology for HSIL) and
clinical details (such as with previous evidence of
HSIL).
b.		 Remaining seven (25%) HSIL cases showed negative
results with p16. The cervical biopsy/cone results

were available in three cases, all of which showed
only HPV changes without dysplasia (confirmed by
p16 on biopsies). A review of initial cytology showed
small atypical parakeratotic cells (SAPK)[20] which
were misinterpreted initially as HSIL cells (technically
should have been ASC-H).[20]

II. Fifty cases with LSIL cytology

a.		 Thirteen (26%) cases showed positive results with p16.
Out of these, 12 cases had biopsies, all of which were
positive for CIN1 or above lesion.
b. Remaining 37 (74%) LSIL cases showed negative results with p16. Cervical biopsies were available in 12
cases, all of which were negative for dysplasia but 9
(75%) of these biopsies showed the HPV cytopathic
effect.

III. Twenty-one cases with ASC-H cytology

a.		 Fourteen (67%) cases showed positive results with
p16.
		 Cyto–histo correlation was available during the period
of study in six cases. Out of these, five cases showed
CIN 3/carcinoma in situ (CIS)/Ca. The remaining one
case showed CIN 1, but the cyto–histo correlation suggested that the lower grade findings in biopsy may have
been related to sampling artifact with under-sampling.
A review of cytology of all these ASC-H cases retrospectively
showed cytomorphology favoring HSIL and could have been
interpreted definitively as HSIL.
b.		 The remaining seven (33%) ASC-H cases showed
negative results with p16. Cyto–histo correlation was
available during the period of study in five cases.
The 60% (3/5) were negative for dysplasia and 40%
(2/5) were positive with CIN 3 in one and CIN 1
in the other. A review of initial cytology in both
cases showed scant ASC-H cells and suggested the

Table 2: Correlation of p16 immunostaining on cell block sections of LBC specimens with biopsy results
Cytology

HSIL (total cases 28)
LSIL (total cases 50)
ASC-H (total cases- 21)
ASCUS (total cases- 14)
NILM (total cases- 20)

p16 results on
cell block

Correlation with cervical biopsy
Positive cervical biopsy
(CIN1 and above)

Negative cervical biopsy (HPV
or negative for dysplasia)

Biopsy not
available

Total

Positive (21)

11

1

9

21

Negative (7)

0

3

a

4

7

Positive (13)

12

0

1

13

Negative (37)

0

12

22

37

Positive (14)

5

1

8

14

Negative (7)

2

b

3

2

7

Positive (0)

0

0

0

0

Negative (14)

0

0

14

14

Positive (0)

0

0

0

0

Negative (20)

0

0

20

20

Biopsy showed HPV in all three cases with negative p16 on immunohistochemistry of biopsy. A reeview of initial cytology showed that the abnormal cells interpreted as HSIL
were small atypical parakeratotic cells (SAPK).[18]; bReview of initial cytology in both cases showed scant ASC-H cells and suggested sampling artifact in cell block sections
immunostained for p16.
a

4
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possibility of sampling artifact with the absence of
representative abnormal cells in cell block sections
immunostained for p16.

IV. Fourteen cases with ASCUS cytology
a

b

c

d

Figure 2: a) Pap smear interpreted as LSIL, b) H and E cell block sections, c)
p16-stained cell block sections, d) biopsy showing CIN II-III.

		 All 14 (100%) cases showed negative results and biopsies were not available in any. The total number
of ASCUS cases could not be higher due to practical
limitation of unavailability of samples in the majority of the cases, where the residual LBC was sent for
reflex HPV testing. As the current specimens were
not sent for HPVT during this ASCUS interpretation,
they were available for cell block preparation for
this study. Out of these 14 cases, results of HPVT
performed in last 6 months were available in seven
cases. Out of these seven cases, HPVT was positive
in three (43%) cases.
Sensitivity and specificity were calculated only for definitive categories (HSIL and LSIL) using results on cases
with unequivocal biopsy results [Tables 3 and 4]. The
sensitivity for p16 in HSIL cases was 100% with specificity
of 75%. The sensitivity for p16 in LSIL cases was 100%
with specificity of 100% [Tables 3 and 4].

b

a

c

d

Figure 3: a) ASC-H (rare single cells with hyperchromatic nuclei and high
N:C ratios), b) H and E stained cell block sections, c) p16-stained sections
highlighting scattered high-grade cells, d) biopsy showing CIN III with
extensive endocervical glandular involvement.

a

b

c

d

Figure 4: a) Pap smear interpreted HSIL, b) H and E cell block section
containing “microbiopsies”, c) p16-stained cell block section showing true
nuclear positivity, d) biopsy showing invasive squamous cell carcinoma.

DISCUSSION
HPV is a proven carcinogen for cervical cancers and p16 is
an excellent surrogate marker for HPV-related dysplasia.[21]
p16 is a cell-cycle inhibitor that binds to cyclin-dependent
kinase 4 (CDK4) and prevents the phosphorylation and
subsequent inactivation of the retinoblastoma protein
(pRb).[21] A reciprocal relation between p16 and pRb
expression has been observed.[22] Integration of high-risk
HPV DNA into the host genome results in the overexpression of viral proteins E6 and E7. E7 binds to and inactivates
pRB ultimately leading to overexpression of p16 through
a negative feedback loop. [23,24] The overexpression of
p16 indicates already advanced interference of the viral
oncoproteins with cellular proteins involved in cell cycle
regulation. This phenomenon translates into nuclear immunoexpression of p16 in squamous epithelial cells and
correlates with HPV-related dysplasia.[25,26]
A recent meta-analysis of 61 studies published until 2007
on p16 immunoexpression which included 27 studies
on cytologic specimens and 34 studies on cervical biopsies.[10] The analysis concluded that p16 immunostaining correlated with severity of cytological/histological
abnormalities. However, the reproducibility was limited
due to insufficiently standardized interpretation of the
immunostaining. They recommended that a consensus
needs to be reached for assessing p16 immunostaining. In
addition, it needs to be assessed in various clinical settings
addressing relevant management decisions.
5
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Table 3: Sensitivity, specificity, positive predictive value, and negative predictive value for HSIL category
with p16 immunostaining on cell block sections of 15 LBC specimensa
Positive biopsy (CIN1 or above)

Negative biopsy (HPV alone
or negative for dysplasia)

Total
12

HSIL with p16 positive results on cell block (12)

11 (TP)

1 (FP)

HSIL with p16 negative results on cell block (3)

0 (FN)

3 (TN)

3

Total

11

4

15a

Sensitivity TP/(TP+FN)

1.00

Specificity TN/(FP+TN)

0.75

PPV (positive predictive value) TP/(TP+FP)

0.92*

NPV (negative predictive value) TN/(TN+FN)

1.00#

TP, True positive; FP, False positive; FN, False negative; TN, True negative; aOnly cases with cyto–histo correlation with biopsy were considered for these calculations;
*
The probability that the test would be True Positive is 0.9 and False Positive is 0.08; # The probability that the test would be True Negative is 1 and False Negative is 0

Table 4: Sensitivity, specificity, positive predictive value, and negative predictive value for the LSIL category
with p16 immunostaining on cell block sections of 24 LBC specimensa
Positive biopsy (CIN1 or above)

Negative biopsy (HPV alone
or negative for dysplasia)

Total
12

LSIL with p16 positive results on cell block (12)

12 (TP)

0 (FP)

LSIL with p16 negative results on cell block (12)

0 (FN)

12 (TN)

12

Total

12

12

24a

Sensitivity TP/(TP+FN).

1.00

Specificity TN/(FP+TN).

1.00

PPV (positive predictive value) TP/(TP+FP)

1.0*

NPV (negative predictive value) TN/(TN+FN)

1.00#

TP, True positive; FP, False positive; FN, False negative; TN, True negative; aOnly cases with cyto–histo correlation with biopsy were considered for these calculations;
*
The probability that the test would be True Positive is 1 and False Positive is 0; # The probability that the test would be True Negative is 1 and False Negative is 0.

Out of 27 studies performed on cytological specimens,
only 2 utilized cell block sections from residual cytology
specimens.[17,18] Remaining studies (n = 25) either utilized cytologic preparations or had not mentioned the
details of preparation. Recently in 2010, one more study
applied cell blocks to evaluate p16 immunoexpression
in cytology specimens.[27] Data from these studies also
support our finding that p16 is a useful marker for the
objective confirmation of CIN on cell blocks of cervical
cytology specimens. However, cell block preparation
methods were not standardized for achieving sections
with good cellularity along the cutting surface of such
cell blocks.[11]
A review of these studies, surprisingly, highlights a critical
flaw that the exact criteria for interpretation of p16 immunoreactivity as a marker of HPV-related dysplasias are
significantly variable.[10] Studies mostly support nuclear
immunoreactivity with or without cytoplasmic immunostaining in morphologically squamous epithelial cells is
consistent with HPV-related squamous dysplasia — irrespective of the number of cells.[5-7,14,15,28]
Only 6 out of 61 studies in the meta-analysis spelled out
the interpretation criteria for the p16 immunoreactiv6

ity pattern stressing nuclear immunoreactivity with or
without cytoplasmic staining as diagnostic.[10] Others,
however, stated positive p16 immunoreactivity as nuclear
and/or cytoplasmic staining implying that cytoplasmic
immunoreactivity alone is also positive or else did not
mention the criteria. This pattern of interpretation would
obviously introduce potentially false-positive interpretations in such studies.
HPVT has been recommended as ancillary reflex test for
managing ASCUS cytopathologic interpretations.[29] Application of the HPVT in the concert with p16 will add
further perspective as p16-positive and p16-negative cases
supporting disruption or nondisruption of the cell cycle. If
an HPVT is positive, then the p16-negative status indicates
that the lesion is in a nondysplastic state, while the p16positive pattern indicates that the lesion is in a dysplastic
phase. Such stratification may be of practical value especially
in low risk postmenopausal women and adolescents.
Bose et al. reported that the highest rate of positivity (80%)
and the highest levels of expression (more than three to
five positive cells/10× field) were seen in HSIL and ASCH cases. On the other hand, p16 positivity was noted in
only 21% of LSIL and ASC-US cases. They concluded that,
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Pap test with LBC
Positive for
squamous epithelial lesion
Prepare cell block
for reflex p16 testing

ASCUS, LSIL,

1

ASC-H, LSIL-H , HSIL

H&E stained level shows
adequate cellularity
p16 immunostaining
in adjacent cell block section
Positive

Colposcopic
biopsy W ECC
Negative

2Follow upAnnual Pap
1Ref # 34
Shidham et al (2007).

p16 immunostaining
in adjacent cell block section

Negative

Positive

2Follow upAnnual Pap

Colposcopic
biopsy W ECC

Positive

Positive

Negative

Positive

Follow up cytology
at 4-6 month.

Negative

ASCCP PROTOCOL

Negative

2Follow upAnnual Pap

3For biopsy confirmed
2Ref# 32 ASCCP guidelines available at:

3Ref# 32 ASCCP guidelines available at:

For cytologic interpretations:
http://www.asccp.org/pdfs/consensus/algorithms.pdf

For biopsy confirmed disease:
http://www.asccp.org/pdfs/consensus/algorithms_hist.pdf

Figure 5: The recommended management algorithm using reflex p16 immunostaining on cell block sections of LBC specimens.

given that only a minority of LSIL cases progress on to
higher-grade lesions, p16 might be useful for triaging these
patients for closer follow-up and/or further evaluation.[30]
del Pino et al. in a recent report also reported comparative
results on histopathology.[31]
In our study, the majority of ASCUS (14 out of 14, 100%)
and LSIL (37 out of 50, 74%) cases were negative for
p16 in cytology specimens and in biopsy (equivalent
to negative for dysplasia). Although this may appear as
overdiagnosis, many of these cases were positive for either
HPVT performed in the past 6 months (in 3 out of 7, 43%
ASCUS cases) or the HPV cytopathic effect in biopsy (9
out of 12, 75% LSIL cases), consistent with HPV infection
without dysplasia. If we consider this as overdiagnosis for
dysplasia (not for HPV infection without dysplasia as the
biological status) then ASCUS and LSIL cytopathologic
interpretations although not uncommon, can be corrected
with objective ancillary contribution by reflex p16 on cell
block sections (Rp16) on the residual cervical cytology
specimen. Based on the design of this study, concurrent
HPVT on the same specimen could not be performed because the entire residual specimen was used for cell block
preparation for p16 immunostaining.

The application of Rp16 on cell blocks of positive cytology
specimens has very high potential of targeting selective
intervention and preventing nonindicated invasive procedures by identifying p16 positive subset with increased
probability of higher-grade lesions. This p16 assisted
approach with reduced intervention should decrease the
morbidity and cost associated with potential overtreatment.[4] The p16 immunoexpression pattern in cytology specimens with positive cytologic interpretation for
squamous epithelial lesions such as ASCUS, LSIL, ASC-H
(including LSIL cannot rule out high grade (LSIL-H)[32]),
and HSIL could steer definitive management with significant savings and prevention of avoidable interventions.
A comprehensive prospective ASCUS–LSIL Traige Study
(ALTS) type multiinstitutional study evaluating Rp16 on
cell block sections of residual cervical cytology specimens
with positive results (ASCUS and above) in comparison to
other alternatives including the HPV status would benefit
patients and should be initiated with cost analysis. In addition to other benefits, such a prospective multiinstitutional
study will achieve higher number of cases by including
almost all potential specimens by preventing unavoidable
exclusion of any of these relatively rare cases in routine
setting similar to this study.
7
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Currently, tests and procedures such as HPVT, colposcopy,
and biopsy are applied to manage various cytologic interpretations as recommended by American Society for
Colposcopy and Cervical Pathology (ASCCP).[33] However,
all these techniques are resource and manpower intensive, with related patient discomfort (colposcopy) and
morbidity (cervical biopsy/conization) such as hemorrhage, cervical stenosis, cervical incomptence, and preterm
delivery.[4,34] HPVT is noninvasive, but it lacks specificity and only identifies the subset of cases with higher
risk without any information-related to the absence or
presence of dysplasia, which is a better decisive feature
deciding the definitive management to minimize the invasive encounters. The specificity without decreasing the
sensitivity of cervical cytology interpretations is highly
desirable. This may be optimized by introducing the Rp16
as ancillary test[35] on appropriately prepared cell block in
all cases with positive cytologic interpretations. This allows
an excellent noninvasive opportunity for appropriate decision making in the management algorithm. Rp16 on cell
blocks of the residual LBC specimen in all positive cytology
interpretations would achieve these features [Figure 5] and
lead to significant savings with opportunity to decrease
morbidity. The cell block protocol used in this study is an
economical and easily available method.[11]

endocervical curettage; H & E, Hematoxylin and Eosin;
HPV, human papilloma virus; HPVT, HPV DNA testing;
HSIL, high-grade squamous intraepithelial lesion; p16,
p16INK4a; IHC, immunohistochemistry; IRB, institutional review board; LBC, liquid based cytology; LSIL, lowgrade squamous intraepithelial lesion; LSIL-H, low-grade
squamous intraepithelial lesion, cannot exclude HSIL;
NILM, negative for intraepithelial lesion or malignancy; Pap
test, cervical cytology; pRb, retinoblastoma protein; Rp16,
Reflex p16; SAPK cells, small atypical parakeratotic cells;
SCIP, subtractive coordinate immunoreactivity pattern; SP,
SurePathTM specimen (TriPath Imaging, Burlington, NC).

The cell block sections have additional benefits of sequential sectioning and immunostaining with other additional
immunomarkers and future techniques including two
color immunostaining.[13,36] The location of AV marker
in the section allows the application of the subtractive
coordinate immunoreactivity pattern (SCIP) approach for
proper evaluation of multiple immunomarkers in serial
levels of cell block sections with singly scattered cells.[37,38]

The authors appreciate and thank Glen Dawson, BS, HT,
IHC(ASCP), Jerome Jacobson, HT, QIHC(ASCP), and Katherine
Wertz, BS,HTL,QIHC(ASCP) for the technical immunocytochemistry assistance. We also thank Anushree Shidham for her
secretarial and copy-editing support.

It is concluded that p16 on cell block sections of cervical
cytology specimens with positive squamous interpretation
including ASCUS, LSIL, ASC-H, LSIL-H, and HSIL showed
distinct patterns with excellent correlation with biopsy
results. Rp16 immunostaining of cell blocks prepared by
a properly standardized protocol is recommended. An
algorithmic approach with reference to p16 results to manage cytologically positive squamous lesions is proposed
[Figure 5]. A multiinstitutional comprehensive prospective
study to evaluate this approach is recommended as the
next step to evaluate this algorithm with cost analysis.

List of abbreviations

ALTS, ASCUS-LSIL Triage Study; ASCCP, American Society
for Colposcopy and Cervical Pathology; ASC-H, Atypical
squamous cells Cannot exclude high-grade intraepithelial
lesion; ASCUS, Atypical squamous cells of undetermined
significance; Ca, invasive carcinoma; CDK4, cyclin-dependent kinase 4; CIN, cervical intraepithelial neoplasia; ECC,
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